- conflicts or gaps
- [{"name_branding_mismatch": {"value": "YC URL/slug is viosera-therapeutics but YC page displays ResistanceBio branding and lists founders as Former Founders", "source_urls": ["https://www.ycombinator.com/companies/viosera-therapeutics"]}, "founding_year_discrepancy": {"value": "Sources report 2016 (YC, Tracxn, CBInsights), 2018 (Reforgers), and 2019 (Employbl for ResistanceBio)", "source_urls": ["https://www.ycombinator.com/companies/viosera-therapeutics", "https://reforgers.com/startups/resistancebio", "https://www.employbl.com/companies/resistancebio"]}, "location_discrepancy": {"value": "Headquarters reported as St Louis (Viosera), Sunnyvale (YCDB), Menlo Park (SEC/CBInsights/Tracxn), and San Carlos (Sahsen/LinkedIn/LeadIQ)", "source_urls": ["https://www.ycdb.co/company/viosera-therapeutics", "https://www.sec.gov/Archives/edgar/data/2010024/000201002424000001/0002010024-24-000001-index.htm", "https://sahsen.com/portfolio/index.php?id=143", "https://www.linkedin.com/company/resistancebio"]}, "employee_count_discrepancy": {"value": "Reported headcount ranges from 2 (LinkedIn/Tracxn 2026) to 15 (YC page) to 10–20 (Employbl)", "source_urls": ["https://www.ycombinator.com/companies/viosera-therapeutics", "https://www.linkedin.com/company/resistancebio", "https://www.employbl.com/companies/resistancebio"]}, "funding_total_discrepancy": {"value": "ResistanceBio total funding reported as $5.5M (2022), $12.78–12.9M (CBInsights/Tracxn), and $24.8M (Employbl/LinkedIn); Viosera reported as $150K (CBInsights) vs undisclosed (Tracxn)", "source_urls": ["https://www.fiercebiotech.com/biotech/could-a-single-pill-treat-a-tumor-today-and-head-off-its-drug-resistance-mechanisms", "https://www.cbinsights.com/company/resistancebio", "https://www.employbl.com/companies/resistancebio", "https://www.cbinsights.com/company/viosera-therapeutics"]}, "operating_status_discrepancy": {"value": "YC and Reforgers list Inactive/shutdown; Tracxn lists Viosera Deadpooled; CBInsights lists both entities Alive; Sahsen lists ResistanceBio Exited without details", "source_urls": ["https://www.ycombinator.com/companies/viosera-therapeutics", "https://reforgers.com/startups/resistancebio", "https://tracxn.com/d/companies/viosera-therapeutics/__k9IBIvWM4WMNA1FpP6OaAgtRY372RclRmmhv6XYzOHg", "https://www.cbinsights.com/company/resistancebio", "https://sahsen.com/portfolio/index.php?id=143"]}, "founder_roster_discrepancy": {"value": "Gautam Dantas listed as Viosera co-founder on Tracxn but absent from YC founder page; Sahsen misspells Nicholas Goldner as Nick Golder", "source_urls": ["https://tracxn.com/d/companies/viosera-therapeutics/__k9IBIvWM4WMNA1FpP6OaAgtRY372RclRmmhv6XYzOHg", "https://www.ycombinator.com/companies/viosera-therapeutics", "https://sahsen.com/portfolio/index.php?id=143"]}, "ceo_succession_gap": {"value": "Kyle Lapham served as CEO Dec 2023–Dec 2024 during $12.8M raise; Tracxn still lists Nicholas Goldner as current CEO as of June 2026; Goldner departed resistanceBio Jul 2024 per LinkedIn", "source_urls": ["https://linkedin.com/in/kylelapham", "https://www.intelligence360.news/resistancebio-has-filed-a-notice-of-an-exempt-offering-of-securities-to-raise-12776288-00-in-new-equity-and-debt-financing/", "https://tracxn.com/d/companies/resistancebio/__ilIW0eN4D6u6A1VD6VixnJzrv71dnZYqzFSpQN_HdUc", "https://linkedin.com/in/nicholas-goldner"]}, "website_offline": {"value": "resistance.bio domain appears parked/for sale; operational status unclear", "source_urls": ["https://www.resistance.bio/"]}, "litigation_details_gap": {"value": "Harlow Special Opportunities Fund lawsuits pending in Texas state and federal courts; complaint allegations and outcomes not available in public docket summaries reviewed", "source_urls": ["https://unicourt.com/case/tx-dl3-harlow-special-opportunities-fund-i-lp-vs-viosera-therapeutics-inc-et-al-106263", "https://www.pacermonitor.com/public/case/54087743/Harlow_Special_Opportunities_Fund_I_LP_v_Viosera_Therapeutics_Inc_et_al"]}, "exit_type_unspecified": {"value": "Sahsen marks ResistanceBio as Exited but does not disclose acquirer, date, or terms; no matching public M&A announcement found", "source_urls": ["https://sahsen.com/portfolio/index.php?id=143", "https://www.employbl.com/companies/resistancebio"]}}]
- source urls
- ["https://leadiq.com/c/resistancebio/6211273e0f6952540d64d31c", "https://linkedin.com/in/kylelapham", "https://linkedin.com/in/nicholas-goldner", "https://reforgers.com/startups/resistancebio", "https://sahsen.com/portfolio/index.php?id=143", "https://tracxn.com/d/companies/resistancebio/__ilIW0eN4D6u6A1VD6VixnJzrv71dnZYqzFSpQN_HdUc", "https://tracxn.com/d/companies/viosera-therapeutics/__k9IBIvWM4WMNA1FpP6OaAgtRY372RclRmmhv6XYzOHg", "https://unicourt.com/case/tx-dl3-harlow-special-opportunities-fund-i-lp-vs-viosera-therapeutics-inc-et-al-106263", "https://www.cbinsights.com/company/resistancebio", "https://www.cbinsights.com/company/viosera-therapeutics", "https://www.employbl.com/companies/resistancebio", "https://www.fiercebiotech.com/biotech/could-a-single-pill-treat-a-tumor-today-and-head-off-its-drug-resistance-mechanisms", "https://www.intelligence360.news/resistancebio-has-filed-a-notice-of-an-exempt-offering-of-securities-to-raise-12776288-00-in-new-equity-and-debt-financing/", "https://www.linkedin.com/company/resistancebio", "https://www.pacermonitor.com/public/case/54087743/Harlow_Special_Opportunities_Fund_I_LP_v_Viosera_Therapeutics_Inc_et_al", "https://www.resistance.bio/", "https://www.sec.gov/Archives/edgar/data/2010024/000201002424000001/0002010024-24-000001-index.htm", "https://www.ycdb.co/company/viosera-therapeutics", "https://www.ycombinator.com/companies/viosera-therapeutics"]